71e02fc571b87f50f6d984f0cbc4954595f651c1 abenetpa Mon Aug 3 17:08:52 2020 -0700 finished description page ClinGen composite ref #24818 diff --git src/hg/makeDb/trackDb/human/clinGen.html src/hg/makeDb/trackDb/human/clinGen.html index 7ce2f1f..57ee5dc 100644 --- src/hg/makeDb/trackDb/human/clinGen.html +++ src/hg/makeDb/trackDb/human/clinGen.html @@ -41,44 +41,91 @@ href="https://www.nlm.nih.gov/">National Center for Biotechnology Information (NCBI)</a> of the <a target="_blank" href="https://www.nlm.nih.gov/">National Library of Medicine (NLM)</a> which distributes part of this information through its <a target="_blank" href="https://www.ncbi.nlm.nih.gov/clinvar/">ClinVar</a> database. </p> <p> The available data tracks are: <ul> <li><b>Clinical Genome Resource Structural Variants (ClinGen Structural Variants)</b> - Shows curated copy number variants (CNVs) with sufficient pathogenic or benign evidence as a mechanism for disease from the dbVar study <a target="_blank" href="https://www.ncbi.nlm.nih.gov/dbvar/studies/nstd45/">nstd45</a> (ClinGen Curated Dosage Sensitivity Map-obsoleted). </li> -<li><b>Clinical Genome Resource Dosage Sensitivity (ClinGen Dosage Sensitivity)</b> - +<li><b>Clinical Genome Resource Dosage Sensitivity Map Haploinsufficiency (ClinGen Haploinsufficiency) and -Triplosensitivity (ClinGen Triplosensitivity)</b> - Shows evidence supporting or refuting haploinsufficiency (loss) and triplosensitivity (gain) as mechanisms for disease at gene-level and larger genomic regions. </li> </ul> </p> - +<p> +A <b>rating system</b> is used to classify the <b>evidence</b> supporting or refuting dosage + sensitivity for individual genes and regions, which takes in consideration the following criteria: +number of causative mutations reported, patterns of inheritance, consistency of phenotype, evidence +from large-scale case-control studies, mutational mechanisms, data from public genome variation +databases, and expert consensus opinion. +</p> +<p> +The system is intended to be of a "dynamic nature", with regions being reevaluated periodically to +incorporate emerging evidence. The evidence collected is displayed within a publicly available +<a target="_blank" href="https://search.clinicalgenome.org/kb/gene-dosage">database</a>. +Evidence that haploinsufficiency or triplosensitivity of a gene is associated with a specific +phenotype will aid in the interpretive assessment of CNVs including that gene. +</p> <h2>Display Conventions</h2> <p> +<b>Structural Variants</b> are shaded according to variant type, +<b><font color="red">red</font color></b> for CNV loss, <b><font color="blue"> blue</font color></b> +for CNV gain. +<p> +Mouseover on items indicates affected protein-coding genes, size of the variant, variant type, and +associated phenotype. When more than 2 genes are affected by a variant, the full +list can be obtained by clicking on the item and reading the details page. +</p> +<p> +All tracks can be filtered according to the size of the variant, variant type (loss or gain), and +clinical significance (benign or pathogenic). +</p> +<p> +<b>Dosage Scores</b> are used to classify the evidence of the supporting dosage sensitivity map: +<dl> +<dd><b>0</b> - no evidence available</dd> +<dd><b>1</b> - little evidence for dosage pathogenicity</dd> +<dd><b>2</b> - some evidence for dosage pathogenicity</dd> +<dd><b>3</b> - sufficient evidence for dosage pathogenicity</dd> +<dd><b>30</b> - gene associated with autosomal recessive phenotype</dd> +<dd><b>40</b> - dosage sensitivity unlikely</dd> +</dl> +</p> +For more information on the use of the scores see the ClinGen +<a target="_blank" href="https://clinicalgenome.org/tools/cnv-webinar/faq/">FAQs</a>. +Items are shaded according to dosage sensitivity type. <b><font color="red">red</font></b> for haploinsufficiency, +<b><font color="blue">blue</font></b> for triplosensitivity, +and <B><font color="#a8a8a8">grey</font></b> for other evidence scores or +for genes/regions that have not been evaluated yet or no evidence is available. A light to dark +gradient color is used according to the degree of supporting evidence. +</p> +<p> +Mouseover on items shows the supporting evidence of dosage sensitivity and respective scores. All +tracks can be filtered according to the supporting evidence of dosage sensitivity. +</p> +<p> These tracks are multi-view composite tracks that contain multiple data types (views). Each view within a track has separate display controls, as described -<a href="../goldenPath/help/multiView.html">here</a>. Some ClinGen tracks contain multiple -subtracks, corresponding to subsets of data. The user can select which subtracks are displayed via -the display controls on the track details page. +<a href="../goldenPath/help/multiView.html">here</a>. </p> <h2>Data Access</h2> <p> The raw data can be explored interactively with the <a href="../cgi-bin/hgTables">Table Browser</a>, or the <a href="../cgi-bin/hgIntegrator">Data Integrator</a>. For automated analysis, the data may be queried from our REST API. Please refer to our <a href="https://groups.google.com/a/soe.ucsc.edu/forum/#!forum/genome">mailing list archives</a> for questions, or our <a href="../FAQ/FAQdownloads.html#downloads36">Data Access FAQ</a> for more information. </p> <h2>Credits</h2> <p> Thank you to ClinGen and NCBI, especially Erin Rooney Riggs for technical coordination and